



Journal Homepage: [-www.journalijar.com](http://www.journalijar.com)

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/23450
DOI URL: <http://dx.doi.org/10.21474/IJAR01/23450>



RESEARCH ARTICLE

ADVANCES, CHALLENGES, AND EMERGING THERAPIES IN TUBERCULOSIS: A COMPREHENSIVE REVIEW OF GLOBAL TUBERCULOSIS CONTROL AND FUTURE DIRECTIONS

Reena Sachan¹, Kanika Bhargava¹, Abhishek Singh², Bhupendra Kumar¹, Amitabh Das Shukla², Ebenezer Jeyekumar³ and Rubina Lawrence³

1. Department of Microbiology, Moti Lal Nehru Medical College, Prayagraj (Uttar Pradesh), 211002, India.
2. Department of Pulmonary Medicine, Moti Lal Nehru Medical College, Prayagraj (Uttar Pradesh), 211002, India.
3. Department of Industrial Microbiology, Sam Higginbottom University of Agriculture Technology and Sciences, Prayagraj (Uttar Pradesh), 211007, India.

Manuscript Info

Manuscript History

Received: 10 March 2026
Final Accepted: 12 April 2026
Published: May 2026

Key words:-

Tuberculosis (TB), Multidrug-resistant TB, Extensively drug-resistant TB, Emerging therapies, Bacteriophage therapy

Abstract

Tuberculosis is a leading global cause of infectious morbidity and mortality, disproportionately affecting low- and middle-income countries with high population density and comorbidities like HIV and diabetes. The COVID-19 pandemic disrupted TB control efforts, halting declines in incidence and driving up mortality rates. MDR-TB and XDR-TB pose growing challenges worldwide, requiring prolonged, expensive, and toxic treatment regimens. Rapid assays such as Xpert MTB/RIF and line probe assays enable early detection and resistance profiling, augmented by novel biomarkers and AI for enhanced precision. Standard treatment for drug-sensitive TB remains a six-month regimen, while novel shorter regimens-including all-oral therapies with recently licensed drugs like bedaquiline, delamanid, and pretomanid are redefining MDR/XDR-TB management. Innovations include host-directed therapies that modulate immunity, nanotechnology for targeted drug delivery, and bacteriophage therapy in which phages selectively lyse drug resistant strains, bypassing antibiotics while exhibiting low toxicity. Hurdles persist in standardization and access. Integrated diagnostics, phage like innovations, public health initiatives, equity, and commitment are essential to reverse the epidemic and meet elimination targets.

"© 2026 by the Author(s). Published by IJAR under CC BY 4.0. Unrestricted use allowed with credit to the author."

Introduction:-

Tuberculosis (TB) is a major global health challenge, consistently ranking among the leading causes of morbidity and mortality due to infectious diseases worldwide, as confirmed by both the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC)[1]. According to the WHO Global Tuberculosis Report 2023, an estimated 10.8 million people developed TB globally, with approximately 1.3 million deaths among HIV-negative individuals and an additional 214,000 deaths among HIV-positive individuals[2]. TB is a major public health concern in low- and middle-income nations, particularly in areas with high population density, socioeconomic

Corresponding Author:-Kanika Bhargava

Address:-Department of Microbiology, Moti Lal Nehru Medical College, Prayagraj (Uttar Pradesh), 211002, India

dependency, and comorbidities like diabetes and HIV [3,4]. Its incidence rates have marginally increased following COVID-19 interruptions, reversing the previous decade's 2% yearly decline; a 3.6% increase is observed between 2020 and 2023[5]. Five nations account for 56% of global tuberculosis cases: India (26%), Indonesia (10%), China (6.8%), the Philippines (6.8%), and Pakistan (6.3%) [2]. India's yearly notification reached 26 lakh cases in 2024, with a 17.7% drop in incidence since 2015, however, elimination targets remain extremely challenging[6]. The CDC reiterates these concerns, underlining TB's continuation as a serious respiratory infectious illness in the U.S. and globally, with significant variance in disease burden linked to risk groups such as migrants, the immunocompromised, and senior citizens[1].

Transmission dynamics of Tuberculosis:-

Tuberculosis is caused by the bacterium *Mycobacterium tuberculosis* (MTB), an aerobic, non-spore-forming, non-motile bacillus with lipid-rich cell walls that confer acid-fast properties [7]. This organism has a reproduction rate of approximately 20 hours and takes 3 to 8 weeks to manifest visually on solid media; therefore, laboratory identification is tedious. Airborne droplet nuclei are the primary mechanism of transmission and can remain suspended in the environment for an extended period of time [8]. MTB infection leads to a spectrum of outcomes, ranging from active progressive disease to a clinically dormant, latent state. The specific host and bacterial factors that control the maintenance of latency and trigger reactivation are complex and remain an active area of investigation [9].

Pathogenesis of Tuberculosis: Host-Pathogen Interactions and Disease Progression:-

The pathogenesis of tuberculosis is initiated upon inhalation. Bacilli that evade the mucociliary escalator reach the alveoli, where their phagocytosis by resident macrophages is a critical step that determines the outcome of the infection [10]. The dissemination of bacilli to regional lymph nodes triggers activation of T lymphocyte, which in turn orchestrates the recruitment of diverse immune cells to form granulomas [11]. While these organized structures are designed to contain the infection, the intricate mechanisms governing their function and ultimate fate remain subjects of ongoing research. Radiologically, a Ranke complex indicates healed primary tuberculosis which results from the fibrosis and calcification of an earlier Ghon complex; this late-stage finding is identified by the combination of a calcified parenchymal scar and calcified hilar or mediastinal lymph nodes [12]. Among individuals infected, approximately 5% progress to active disease within the first two years after primary infection, while an additional 5% experience reactivation and develop disease later in life [7]. Active tuberculosis results when host immune control is compromised, with granulomas undergoing caseous necrosis and airway rupture to form cavities [13]. These cavities facilitate high bacillary loads, transmission, foster drug resistance, promote fibrosis, and opportunistic secondary infections [14-16]. Notably, some granulomas do not cavitate and may heal by mechanisms that are not yet fully understood [17]. After an initial infection, an effective CD4⁺ and CD8⁺ T-cell response typically contains the bacteria within three to eight weeks, establishing latent tuberculosis, which can fluctuate between true dormancy and subclinical disease[18]. In adults, most active tuberculosis cases arise from reactivation of latent infection rather than new primary infection (Figure 1). Although prior infection provides partial protection against reinfection, exogenous reinfection can occur, especially in immunocompromised individuals or those with significant exposure [19].




Fig. 1: Pathogenesis of *Mycobacterium tuberculosis*

TB Disease Burden and Risk Determinants in the COVID-19 Era:-

TB remains a major global health challenge [20,21], with approximately 90% of infected individuals harbouring latent infection and around 5% progressing to active disease during their lifetime [7]. In 2022, TB caused an estimated 1.3 million deaths worldwide, marking a slight decline from previous years[21]. The COVID-19 pandemic severely disrupted TB management globally [22], resulting in increased TB mortality due to healthcare system interruptions and the diversion of resources to COVID-19 care, which delayed TB diagnosis and escalated case burdens in subsequent years [23]. Despite decades of advances in prevention and treatment, tuberculosis remains the second leading infectious cause of mortality worldwide, trailing COVID-19 [24]. Surveillance data from 2023 indicated a resurgence of tuberculosis in the United States (US), with 9615 reported new cases[25]. Additionally, TB remains the leading cause of death among people living with HIV, accounting for 167,000 deaths in 2022 alone [26]. Several risk factors predispose individuals to TB progression, including advanced age with immune senescence, genetic immunodeficiencies, HIV infection, organ transplantation, prolonged corticosteroid therapy, cytotoxic chemotherapy, TNF antagonist use, malnutrition, diabetes, smoking, and heavy alcohol consumption [27,28]. Diabetes and HIV both increase the risk of active tuberculosis by impairing host immunity and promoting reactivation of latent infection. Diabetes creates a chronic inflammatory, hyperglycaemic state that disrupts immune cell metabolism and cytokine signalling, while HIV causes immune-cell metabolic stress and chronic activation, and ART-related metabolic effects can further worsen insulin resistance and glucose dysregulation[29, 30]. HIV depletes CD4+ T cells and impairs CD8+ function, and diabetes further weakens T-cell proliferation and cytokine responses, reducing both CD4+ and CD8+ immunity against TB[31, 32]. Because latent TB is normally controlled by coordinated CD4+ Th1, macrophage, and CD8+ responses, the combined metabolic and immunological effects of these conditions create an environment that is unfavourable for containing dormant bacilli and increases the risk of reactivation[33].

Another major challenge is MDR-TB, defined as resistance to at least isoniazid and rifampicin[34]. MDR-TB is particularly prevalent in high-burden regions such as India, China, Russia, and parts of Africa [35]. The most severe type of TB, extensively drug-resistant tuberculosis (XDR-TB), is characterised by additional resistance to fluoroquinolones and second-line injectable drugs such as capreomycin, amikacin, or kanamycin [35]. A study on the prevalence and geographic distribution of certain genotypes found that the Beijing genotype accounted for 31.78% of drug-resistant pulmonary *M. tuberculosis* isolates, primarily affecting younger patients in China [36]. In Luoyang, an MDR-TB prevalence of 11.4% was reported, with males, urban inhabitants, and retreatment cases identified as categories at higher risk [37]. Meanwhile, Western Siberia exhibits some of the highest MDR-TB rates globally, with an increase from 19.2% to 26.4%, constituting 67.9% of MDR-TB cases [38]. Comparatively, the US reported a much lower MDR-TB prevalence of 1.4% in 2023 [39]. Table 1 further details the prevalence of MDR-TB in selected high-burden countries [21].

These epidemiological patterns are further reflected in demographic inequalities, where MDR-TB preferentially affects males [40]. Multiple studies consistently indicate that males have approximately 2 to 3 times higher prevalence drug-resistant TB compared to females, especially in productive age groups under 50 years [41]. A systematic review concluded that males have a higher prevalence of MDR-TB (over 20%) than females (approximately 13%), indicating a higher susceptibility to drug-resistant TB[42]. At the global level, in 2023, an estimated 10.8 million people developed tuberculosis, with multidrug-resistant and rifampicin-resistant TB accounting for about 150,000 deaths worldwide [43]. The management of drug-resistant TB remains highly complex, costly, and is associated with poorer treatment outcomes, posing a significant barrier to its control and elimination efforts [44]. Furthermore, the simultaneous problems of HIV coinfection and drug-resistant tuberculosis, as well as health-care system disruptions induced by the COVID-19 pandemic, have reaffirmed its status as an urgent global health priority. This underscores the significance of continuous surveillance, increased access to suitable treatment, and enhanced public health initiatives.

Table 1: Recent MDR-TB epidemiology country-wise

Country	% Global MDR-TB Cases	MDR-TB in New Cases (%)	MDR-TB in Retreatment Cases (%)	References
India	27%	3.2%	16%	[45]
Russia	7.4%	24%	54%	[46]

China	7.3%	3.2%	16%	[47]
Philippines	7.2%	3%	20%	[46]
Indonesia	7.4%	3.2%	16%	[48]
Namibia	—	5–6%	15–20%	[21]
Pakistan	—	4.2%	18%	[49]

Molecular Characterization and Clinical Relevance of MDR-TB Resistance Mechanisms:-

Molecular characterisation of circulating MDR-TB strains has revealed significant global variability, highlighting the complex genetic landscape that underpins resistance [50,51]. Certain genotypes, particularly the Beijing strain prevalent in northern India and several other high-burden regions, have been closely linked with enhanced virulence and strong association with MDR [52, 53]. Molecular analyses indicate that resistance is primarily driven by mutations in specific loci—most notably the *katG* gene, responsible for isoniazid resistance, and the *rpoB* gene, conferring rifampicin resistance [54]. Across distinct geographical populations, these resistance determinants tend to aggregate within predictable hotspot regions of the genome, pointing to a consistent global pattern of resistance evolution [55]. Multiple studies have demonstrated a recognizable sequence in the acquisition of resistance, wherein isoniazid, resistance typically emerges before rifampicin, suggesting a stepwise process in the genetic adaptation of MTB under selective drug pressure [56,57]. Genotyping data further reinforce the association between particular strain lineages and MDR-TB, with the Beijing genotype frequently identified as a dominant lineage in northern India and East Asia[58,59]. Among the most common resistance-conferring mutations, *katG* S315T is strongly linked to isoniazid resistance, while mutations at *rpoB* codons 516, 526, and 531 are typically associated with rifampicin resistance[60-62]. Despite this, a small but clinically significant set of MDR isolates lack these typical resistance mutations, as reported in a study from Uganda, limiting the detection rate of molecular diagnostic tools such as GeneXpert and line probe assays(LPAs)[63,64].

The implications of such molecular diversity extend beyond basic microbiology to patient outcomes. The accuracy of drug susceptibility testing (DST) plays a pivotal role in successful treatment and survival. Zürcher et al. [65] observed that patients with discordant DST results, meaning that molecular and phenotypic DST outcomes were inconsistent, had twice the risk of mortality as those with concordant test results. This finding underscores the critical importance of reliable, comprehensive genotypic characterization in guiding effective MDR-TB diagnosis, drug selection, and global control strategies.

Advances in Tuberculosis Diagnostics: Molecular, Biomarker, and AI Innovations:-

Recent years have seen substantial progress in TB diagnostics, greatly enhancing the speed and accuracy of disease detection and drug resistance identification. Highly sensitive molecular tests, such as the WHO-endorsed Xpert MTB/RIF assay, enable rapid detection of *M. tuberculosis* and simultaneous identification of rifampicin resistance directly from clinical samples, typically sputum, with sensitivity and specificity of 80-85% and 95-98%[66,67]. This technology has become a critical tool for early and accurate diagnosis, allowing early treatment initiation compared to the weeks required by traditional culture methods [68]. LPAs, based on polymerase chain reaction (PCR) technology, are now recommended for upfront detection of resistance against isoniazid and rifampicin by identifying specific genetic mutations in MTB directly from specimens[69]. Although culture remains the gold standard for tuberculosis diagnosis because of its high specificity and capacity for comprehensive drug susceptibility testing, molecular diagnostics have revolutionized TB detection by providing rapid, sensitive, and user-friendly alternatives suitable for resource-limited settings[70-72]. These assays complement traditional methods by enabling quick screening and early resistance detection, and WHO guidelines recommend their integration as frontline diagnostics to reduce delays and improve treatment outcomes[73]. Recent innovations include the second-generation Xpert Ultra with enhanced sensitivity for detecting paucibacillary and extrapulmonary TB, loop-mediated isothermal amplification (LAMP) assays for simple and rapid point-of-care testing, and next-generation sequencing for comprehensive resistance profiling[74-76]. Additionally, emerging technologies that detect TB antigens offer improved diagnostic accuracy in challenging cases such as extrapulmonary TB[77]. Although higher costs and equipment requirements limit widespread implementation, these advances collectively represent a major step forward in global TB control through earlier detection and effective management of both drug-sensitive and drug-resistant diseases.

Major advances in tuberculosis diagnostics encompass novel biomarkers, molecular tests, artificial intelligence (AI) platforms, and next-generation point-of-care tools that collectively enhance accuracy, speed, and accessibility. Host- and pathogen-derived biomarkers such as IFN- γ , IP-10, ferritin, and Ag85B are being developed to differentiate latent from active disease, predict progression risk, and monitor treatment response, while proteomic and transcriptomic studies have identified high-performing protein panels including FCGR3B, FETUB, LRG1, ADA2, CD14, and SELL[78-80]. Blood-based markers, such as specific microRNAs (miR-143, miR-139, miR-454) and circRNAs, are also under investigation to simplify testing and reduce invasiveness[81,82]. AI algorithms are automating chest X-ray interpretation to detect nodules, consolidations, and cavities with high accuracy, supporting objective screening and diagnosis[83-85]. Deep learning and machine learning models integrate genomic, biomarker, and clinical data to predict TB, drug resistance, and outcomes, often surpassing traditional methods in early detection and reducing misdiagnosis[86-88]. Clinical decision support systems integrate patient history, imaging, and molecular results to guide treatment, particularly in complex MDR and extrapulmonary cases, while AI-driven telemedicine platforms extend diagnostic abilities to resource-limited locations [89,90]. Emerging approaches such as recombinase-aided amplification (RAA) and thermal imaging protocols are being explored for lymph node and extrapulmonary TB to address gaps where conventional testing is limited[91]. The integration of rapid molecular methods with AI analysis streamlines turnaround time and boosts point-of-care performance, enabling timely treatment and strengthening case detection, thus accelerating progress toward global TB elimination goals.

Treatment Strategies and Advances in Tuberculosis Management:-

Standard treatment for drug-susceptible TB involves a six-month regimen, beginning with an intensive two-month phase of four primary drugs: isoniazid, rifampicin, ethambutol, and pyrazinamide, followed by a continuation phase of four months with isoniazid and rifampicin to eliminate residual bacilli and reduce relapse risk. Treatment duration significantly increases and effectiveness decreases for MDR and XDR TB, necessitating prolonged use of second-line agents, which are often associated with adverse side-effects and higher toxicity[34]. The WHO's End TB Strategy aims to reduce TB incidence by 90% and deaths by 95% by 2035[92]; however, ongoing challenges such as drug resistance, TB/HIV coinfection, and the impacts of the COVID-19 pandemic threaten these ambitious goals[93]. These factors underscore the continued urgency for enhanced diagnostics, optimized treatment regimens, and robust public health interventions to control TB globally.

Treatment strategies for TB in 2025 include standardized and novel shortened regimens, newly approved drugs for drug-resistant TB, and advanced therapeutic drug monitoring (TDM) protocols to optimize individual care. The traditional first-line therapy remains the six-month course of isoniazid, rifampicin, ethambutol, and pyrazinamide, while shortened four-month regimens of high-dose rifapentine and moxifloxacin are advised for suitable adults and children with non-severe, drug-sensitive tuberculosis [94,95]. For MDR or rifampicin-resistant TB, WHO recommends all-oral, six-month regimens such as BPaLM (bedaquiline, pretomanid, linezolid, moxifloxacin) and BDLLfxC (bedaquiline, delamanid, linezolid, levofloxacin, clofazimine) based on molecular susceptibility testing[96,97]. Recently approved drugs like bedaquiline, delamanid, and pretomanid form the backbone of all-oral regimens for MDR and XDR TB[98,99]. Linezolid remains essential but is associated with side effects; newer oxazolidinones (sutezolid, tedizolid) are currently in trials showing promising safety and efficacy[100,101]. Meropenem-clavulanate and novel carbapenems such as tebipenem and faropenem are being explored for XDR-TB cases[102,103]. The shift to all-oral regimens reduces risk and improves outcomes compared to previous protocols involving injectables [104,105].

Therapeutic drug monitoring tailors TB therapy by measuring drug levels in plasma, dried blood spots, urine, or hair to account for metabolic variability, organ dysfunction, drug interactions, and adherence[106]. Techniques such as LC-MS/MS, HPLC, and UPLC enable precise, real-time quantification of drugs including rifampicin, isoniazid, bedaquiline, and linezolid, especially for complex cases and vulnerable populations such as MDR/XDR TB patients, those with poor clinical response, HIV coinfection, or liver/kidney dysfunction, and when drugs with narrow therapeutic windows are used[106]. TB guidelines encourage TDM to minimize toxicity and adverse events while maximizing efficacy. This strategic integration of shorter regimens, new drugs, and TDM is reshaping TB treatment outcomes and supporting progress toward global elimination.

Comprehensive Strategies for Tuberculosis Prevention and Control:-

Prevention and control of TB in 2025 involves a combination of vaccination, immunoprophylaxis, comprehensive public health strategies, and integrated care models, especially targeting TB-HIV co-infection[26]. Core prevention focuses on early detection, prompt treatment, and interrupting transmission chains through infection control measures in community and healthcare settings[2]. Preventive treatment for latent TB infection remains vital for high-risk groups such as close contacts, people living with HIV, and immunocompromised individuals[107]. Infection control includes respiratory hygiene, environmental measures such as ventilation and UV light, and personal protective equipment in healthcare environments.

Integrated TB-HIV diagnosis, offer screening and treatment for both conditions at a single site by coordinated teams thereby enhancing outcomes and reduce mortality. WHO guidelines recommend systematic, integrated screening in primary healthcare with operational manuals to support implementation. This integration enhances adherence, reduces loss to follow-up, and facilitates comprehensive care of co-infected patients[2]. The Bacillus Calmette-Guérin (BCG) vaccine remains widely used but offers limited protection against adult pulmonary TB. Novel vaccines, such as M72/AS01E, are under development aiming to prevent infection, disease progression, and transmission[108]. Immunoprophylaxis includes post-exposure vaccination to prevent relapse and therapeutic vaccines that may improve treatment outcomes[109]. Expanding access and coverage of effective vaccines in high-burden regions remains critical to accelerating TB elimination.

Public health strategies emphasize the "Detect - Treat - Prevent - Build" framework, integrating rapid diagnostics and effective treatment through national programs like India's National Tuberculosis Elimination Programme (NTEP), supported by digital monitoring and social support. Active case finding, contact tracing, community engagement, and private sector inclusion are vital to reduce missed cases and improved adherence[110,111]. Addressing social determinants such as nutrition, housing, and poverty through multisectoral collaboration strengthens TB control efforts. Together, these approaches form the foundation of modern TB prevention and control, enhancing care and reducing TB burden and transmission globally

Innovative Research and Emerging Therapies Transforming Tuberculosis Treatment:-

Research innovations in TB in 2025 are centered on novel host-directed therapies (HDTs), advances in nanotechnology for drug delivery, telemedicine and digital health platforms, and emerging bacteriophage therapies[112-116]. HDTs modulate the host immune response rather than directly targeting *M. tuberculosis*, potentially enhancing treatment efficacy, reducing tissue damage, and limiting drug resistance. HDT facilitates repurposing approved drugs such as statins, macrocyclic lactones, tyrosine kinase inhibitors, synthetic opioids, JAK inhibitors, vitamins and others [116] to augment anti TB regimens, mitigate the development of drug resistance, shorten treatment duration, and reduce adverse effects. It also harmful inflammation, promoting autophagy, and improving bacterial clearance, which may shorten treatment duration and improve outcomes, particularly in multidrug-resistant TB[117,118].

Nanoparticles (NPs) serve as targeted, controlled-release drug delivery systems that improve bioavailability, reduce dosages, and minimize toxicity of anti-TB drugs. Biocompatible polymers and carbon nanotubes enable sustained release and enhance cellular uptake, optimizing therapy effectiveness[112,119]. Nanoparticle-based drug delivery systems can enhance anti-tubercular therapy by protecting encapsulated drugs from premature degradation, improving solubility and absorption, and promoting targeted uptake by infected alveolar macrophages and granulomatous lesions [119]. By increasing intracellular drug concentration and enabling sustained release at the site of infection, these systems improve bioavailability while reducing off-target distribution and systemic toxicity[120](Zhuo et al., 2024). Nanotechnology also holds promise for vaccine delivery and diagnostics. Telemedicine facilitates remote diagnosis, treatment monitoring, and adherence support through video directly observed therapy (DOT) and SMS reminders, enhancing patient compliance and outcomes, particularly in resource-limited settings[121]. Digital health interventions offer scalable, cost-effective tools for real-time data capture, personalized patient engagement, and support, crucial for continuity of care and addressing underprivileged populations[122].

Bacteriophages, viruses that specifically infect bacteria, are being explored as novel treatments for drug-resistant TB. Early experimental work demonstrates that phage therapy can complement or substitute antibiotics in difficult-to-treat TB cases under ongoing clinical trials. Phages such as D29 and DS6A have shown efficacy against drug-resistant strains *in vitro* and in infection models[1]. Intravenous administration of phage DS6A in humanized mice

infected with aerosolized *M. tuberculosis* showed improved pulmonary function and reduced bacterial load [1]. Bacteriophages offer advantages including specificity to bacteria, replication at infection sites, and ability to overcome antibiotic resistance mechanisms [123,124]. Multiple mycobacteriophages, including DS-6A, TM4, D29, T7, P4, PDRPv, BTCU-1, Bo4, SWU1, GR-21/T, My-327, Ms6, and Bxz2, have been studied for their therapeutic potential against tuberculosis [125]. These phages target various *Mycobacterium* species, with mechanisms ranging from lysing bacterial cell walls via lysins (e.g., D29, Ms6, BTCU-1), interfering with transcription critical to bacterial survival (T7, P4), to inhibiting bacterial metabolism (SWU1) [126-133]. Their actions result in significant reduction or complete elimination of *M. tuberculosis* and related infections in vitro and in animal models, highlighting their promise as alternatives or adjuncts to conventional TB therapy, especially against drug-resistant strains. However, there are major practical challenges to phage therapy for pulmonary tuberculosis include the emergence of phage resistance, difficulties delivering active phages into caseous lung cavities, and regulatory barriers to clinical use.

Dedrick et al., reported the compassionate use of phages in 20 patients with drug-resistant mycobacterial infections and observed favourable outcomes without adverse effects [134]. *M. tuberculosis* can acquire resistance via receptor changes, CRISPR, restriction–modification systems, or altered cell walls, so research favours multi-phage cocktails and phage–drug combinations to reduce resistant mutants. Efficient delivery into poorly vascularized, necrotic, hypoxic, and fibrotic lesions is limited; targeted pulmonary approaches nebulized/inhaled formulations, dry-powder inhalers, liposomal or nanoparticle encapsulation, intralesional administration via bronchoscopy, and carriers that penetrate granulomas are under study to improve phage stability to reach dormant or biofilm-embedded bacilli [134]. Clinical case series and on-going trials have demonstrated the safety and efficacy of phage therapy, often showing a synergistic effect with antibiotics that enhances bacterial eradication and may potentially resensitize bacteria [135]. Despite progress, challenges include standardizing clinical trials, understanding phage resistance, and optimizing phage cocktails to maximize efficacy and minimizing bacterial escape. Integration of bacteriophage therapy into TB treatment presents a promising strategy against MDR and XDR TB, warranting further controlled trials to confirm long-term safety and efficacy. Robust, standardized clinical trials, international regulatory frameworks, and scalable GMP production are needed before phage therapy can be widely adopted for TB.

Tuberculosis Elimination: Progress, Challenges, and Policy Imperatives for Achieving Global Targets:-

TB elimination depends on coordinated global and national strategies; however, progress remains uneven due to entrenched socioeconomic and health system barriers. The Global Plan to End TB (2023–2030) prioritizes accelerating progress through expanded case detection, investment in new diagnostics, drugs, and vaccines, and integration of TB care within broader health systems [136]. India's NTEP aims to eliminate TB by 2025, five years ahead of global targets. Its four strategic pillars “Detect, Treat, Prevent, and Build” are realized through active case finding, real-time digital surveillance, private sector engagement, rapid molecular diagnostics, adherence support via SMS, and direct benefit transfers for nutritional supplementation [110]. These interventions have significantly reduced TB incidence, mortality, and the number of undiagnosed cases. However, the COVID-19 pandemic disrupted this progress both nationally and internationally, delaying elimination efforts. Globally, countries such as Oman, Qatar, and Saudi Arabia have reported substantial progress, with treatment success rates of 90%, 100%, and 87%, respectively [137]. These successes reflect robust health systems, universal access to rapid molecular diagnostics, and comprehensive management of drug-resistant TB. Central Asian countries—including Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan, benefit from the WHO-supported TB-Free Central Asia Initiative, which promotes rapid diagnostics, integration of TB care into primary health systems, and shorter all-oral regimens for drug-resistant TB [96].

TB treatment, especially for MDR-TB, can place a heavy financial strain on patients and their families because of its long duration and the high cost of second-line drugs. It also has broader social effects, including lost income, reduced productivity, and increased household stress, with many families facing catastrophic costs. Akaluet et al., reported total treatment-related expenses of USD 650 to USD 8266, with average direct and indirect costs of USD 1936.25 and USD 1200.35, respectively, and an overall catastrophic cost burden of 81.58%, meaning many households spent at least 20% of their yearly income on TB care [138]. Beyond the financial burden, treatment can disrupt work, education, and daily life, often increasing dependence on caregivers and worsening vulnerability in low-income households.

Common drivers of success for TB management include strong political commitment, multisectoral collaboration, universal access to WHO-recommended molecular diagnostics, and introduction of shorter all-oral regimens for drug-resistant TB, robust surveillance systems, digital case reporting, and integration of TB services with primary healthcare. Despite these advances, major barriers threaten the achievement of the End TB 2030 targets. Critical challenges include funding gaps, health system inadequacies such as stable power supply, persistent socioeconomic inequities, disruptions caused by the COVID-19 pandemic, the growing burden of drug-resistant TB, gaps in preventive measures and innovation, and barriers faced in accessibility by vulnerable populations such as migrants, children, rural and the urban poor [139,140]. Achieving TB elimination requires policy innovation to strengthen multisectoral collaboration alongside increased investment in research and development of new drugs, vaccines, and diagnostics. Ultimately, progress toward elimination depends on equitable access, resilient health systems, and sustained political will at both national and global levels.

Conclusion:-

Tuberculosis continues to pose a formidable global health challenge despite significant advances in diagnostics, treatment regimens, and prevention strategies. The emergence of multidrug-resistant and extensively drug-resistant strains underscores the urgent need for innovative therapeutic approaches and expanded access to rapid molecular diagnostics. Recent progress in host-directed therapies, nanotechnology-based drug delivery, and bacteriophage therapy offers promising avenues to overcome current limitations, especially in managing resistant infections. Integrating these scientific advances with strengthened public health infrastructures, comprehensive surveillance, and multisectoral policy initiatives is critical to achieving the global End TB targets. Continued investment in research, equitable healthcare access, and addressing social determinants of health remain pivotal for sustainable TB control and eventual global elimination.

Conflict of Interest:-

The authors declare no competing interests.

Funding:-

The authors did not receive support from any organization for the submitted work.

Availability of Data material:-

No datasets were generated or analysed during the current study.

Authors contribution:-

RS and KB hypothesized and designed the research plan. Interpretation of data were made by KB and RS. Drafting of the manuscript were made by KB. Final editing of the manuscript were made by RS, KB, AS, BK, ADS, KP, EJ and RL. All the authors have reviewed the manuscript.

Ethics approval:-

Not applicable

References:-

1. Yang H, Ruan X, Li W, Xiong J, Zheng Y. Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990–2021: a systematic analysis for the Global Burden of Diseases 2021 study. *BMC Public Health*. 2024 Nov 11;24(1):3111. <https://doi.org/10.1186/s12889-024-20664-w>
2. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4—Treatment. Published April 14, 2025. Accessed October 13, 2025. <https://www.who.int/publications/i/item/9789240107243>
3. Bailey SL, Grant P. 'The tubercular diabetic': the impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. *Clinical Medicine*. 2011 Aug 1;11(4):344-7. <https://doi.org/10.7861/clinmedicine.11-4-344>
4. Jarde A, Romano E, Afàq S, Elsony A, Lin Y, Huque R, Elseiy H, Siddiqi K, Stubbs B, Siddiqi N. Prevalence and risks of tuberculosis multimorbidity in low-income and middle-income countries: a meta-review. *BMJ open*. 2022 Sep 1;12(9):e060906. <https://doi.org/10.1136/bmjopen-2022-060906>

5. Falzon D, Zignol M, Bastard M, Floyd K, Kasaeva T. The impact of the COVID-19 pandemic on the global tuberculosis epidemic. *Frontiers in Immunology*. 2023 Aug 29;14:1234785. <https://doi.org/10.3389/fimmu.2023.1234785>
6. Ahirwar G, Bhatia M, Pandey V, Mitra B, Sharma Y, Rai V. Estimate of TB incidence and a critical analysis of programmatic data of TB score from Sub national Certification survey of district Niwari, MP, India. *Journal of Family Medicine and Primary Care*. 2025 Jul 1;14(7):2997-3002. DOI: 10.4103/jfmnc.jfmnc_129_25
7. Tobin EH, Tristram D. Tuberculosis Overview. [Updated 2024 Dec 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441916/>
8. Rezaei M, Netz RR. Airborne virus transmission via respiratory droplets: Effects of droplet evaporation and sedimentation. *Current opinion in colloid & interface science*. 2021 Oct 1;55:101471. <https://doi.org/10.1016/j.cocis.2021.101471>
9. Mohammadnabi N, Shamseddin J, Emadi M, Bodaghi AB, Varseh M, Shariati A, Rezaei M, Dastranj M, Farahani A. Mycobacterium tuberculosis: the mechanism of pathogenicity, immune responses, and diagnostic challenges. *Journal of clinical laboratory analysis*. 2024 Dec;38(23):e25122. <https://doi.org/10.1002/jcla.25122>
10. Warner DF, Barczak AK, Gutierrez MG, Mizrahi V. *Mycobacterium tuberculosis* biology, pathogenicity and interaction with the host. *Nature Reviews Microbiology*. 2025 Jun 30:1-7. <https://doi.org/10.1038/s41579-025-01201-x>
11. Sholeye AR, Williams AA, Loots DT, Tutu van Furth AM, van der Kuip M, Mason S. Tuberculous granuloma: emerging insights from proteomics and metabolomics. *Frontiers in Neurology*. 2022 Mar 21;13:804838. <https://doi.org/10.3389/fneur.2022.804838>
12. Pattapaspong N, Kanthawang T, Peh WC, Hammami N, Bouaziz MC, Ladeb MF. Imaging of thoracic tuberculosis: pulmonary and extrapulmonary. *BJR| Open*. 2024 Jan;6(1):tzae031. <https://doi.org/10.1093/bjro/tzae031>
13. Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F. The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?. *Journal of Immunology Research*. 2012;2012(1):139127. <https://doi.org/10.1155/2012/139127>
14. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. *Lancet*. 2016 Jul 9;387(10024):1211-26. doi: 10.1016/S0140-6736(15)00151-8.
15. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review. *Tuberculosis (Edinb)*. 2011 Sep;91(6):497-509. doi: 10.1016/j.tube.2011.04.002.
16. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. *Eur Respir Rev*. 2018 Feb 27;27(147):170077. doi: 10.1183/16000617.0077-2017.
17. Lyu J, Narum DE, Baldwin SL, Larsen SE, Bai X, Griffith DE, Dartois V, Naidoo T, Steyn AJ, Coler RN, Chan ED. Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals. *Frontiers in Immunology*. 2024 Dec 9;15:1427559. <https://doi.org/10.3389/fimmu.2024.1427559>
18. Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N. Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis. *Frontiers in immunology*. 2014 Apr 22;5:180. <https://doi.org/10.3389/fimmu.2014.00180>
19. Marshall GB, Babar JL, Müller NL. Postprimary tuberculosis. *Radiol Clin North Am*. 2007 Jul;45(4):651-67. doi: 10.1016/j.rcl.2007.03.005
20. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. *European Respiratory Journal*. 2019 Sep 12;54(3). <https://doi.org/10.1183/13993003.00655-2019>
21. WHO. Tuberculosis resurges as top infectious disease killer [Internet]. *Who.int*. 2024 [cited 2025 Sep 22]. Available from: <https://www.who.int/news/item/29-10-2024-tuberculosis-resurges-as-top-infectious-disease-killer>
22. Nadji SA, Varahram M, Marjani M, Sadr M, Seyedmehdi SM, Bayat S, Hassani S. COVID-19 pandemic and tuberculosis control: A narrative review. *Tanaffos*. 2022 Apr;21(4):408. PMID: PMC10423866 PMID: 37583775
23. Williams V, Vos-Seda AG, Calnan M, Mdluli-Dlamini L, Haumba S, Grobbee DE, Klipstein-Grobush K, Otvombe K. Tuberculosis services during the COVID-19 pandemic: A qualitative study on the impact of COVID-19 and practices for continued services delivery in Eswatini. *Public Health in Practice*. 2023 Dec 1;6:100405. <https://doi.org/10.1016/j.puhip.2023.100405>

24. Falzon D, Zignol M, Bastard M, Floyd K, Kasaeva T. The impact of the COVID-19 pandemic on the global tuberculosis epidemic. *Frontiers in Immunology*. 2023 Aug 29;14:1234785. <https://doi.org/10.3389/fimmu.2023.1234785>
25. Williams PM. Tuberculosis—United States, 2023. *MMWR. Morbidity and mortality weekly report*. 2024;73.
26. Sossen B, Kubjane M, Meintjes G. Tuberculosis and HIV coinfection: progress and challenges towards reducing incidence and mortality. *International Journal of Infectious Diseases*. 2025 Mar 8;107876. doi: 10.1016/j.ijid.2025.107876.
27. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. *Annual review of medicine*. 2011 Feb 18;62(1):141-55. doi: 10.1146/annurev-med-042909-093756.
28. Jin J, Pan S, Chen J, Yin J, Ba H, Hou H, Zhang Y, Ma K. Prevalence, Risk Factors, and Clinical Outcomes with Advanced HIV Disease Among People with Newly Diagnosed HIV During the “Treat-All” Era: A Retrospective Cohort Study From Xi’an City, China. *Infection and Drug Resistance*. 2025 Dec 31:2427-38. doi: 10.2147/IDR.S518809
29. Gupta S, Shenoy VP, Bairy I, Srinivasa H, Mukhopadhyay C. Diabetes mellitus and HIV as co-morbidities in tuberculosis patients of rural south India. *Journal of infection and public health*. 2011 Aug 1;4(3):140-4. <https://doi.org/10.1016/j.jiph.2011.03.005>
30. Akumu JE, Sekagya-Wiltshire C, Babirye S, Musaazi J, Kukundakwe PE, Okiira C, Mutebi E, Nabadda S, Namuwenge P, Sendagire H. Diabetes mellitus, TB, and HIV multi-morbidities among adults in Uganda. *Public Health Action*. 2026 Mar 1;16(1):63-8. doi: 10.5588/pha.25.0032
31. Ayrga S, Koorsen G. Metabolic reprogramming in HIV+ CD4+ T-cells: implications for immune dysfunction and therapeutic targets in M. tuberculosis co-Infection. *Metabolites*. 2025 Apr 22;15(5):285. doi: 10.3390/metabo15050285
32. Cheng P, Wang L, Gong W. Cellular immunity of patients with tuberculosis combined with diabetes. *Journal of Immunology Research*. 2022;2022(1):6837745. doi: 10.1155/2022/6837745
33. Oni T, Berkowitz N, Kubjane M, Goliath R, Levitt NS, Wilkinson RJ. Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control. *European Respiratory Journal*. 2017 Jul 20;50(1). doi: 10.1183/13993003.00004-2017.
34. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. *Cold Spring Harbor perspectives in medicine*. 2015 Sep 1;5(9):a017863. doi: 10.1101/cshperspect.a017863.
35. Diriba G, Alemu A, Yenew B, Ayano BZ, Hailu M, Buta B, Wondimu A, Tefera Z, Meaza A, Seid G, Getahun M. Second-line drug resistance among multidrug-resistant tuberculosis patients in Ethiopia: A laboratory-based surveillance. *Journal of Global Antimicrobial Resistance*. 2025 May 1;42:167-74. doi: 10.1016/j.jgar.2025.02.014.
36. Kumar A, Verma AK, Kant S, Prakash V, Srivastava A, Srivastava K, Jain A, Srivastava KK. A study on Beijing genotype in the clinical isolates of pulmonary drug-resistant tuberculosis. *Lung India*. 2017 Sep 1;34(5):430-3. doi: 10.4103/lungindia.lungindia_451_16
37. Wang Z, Hou Y, Guo T, Jiang T, Xu L, Hu H, Zhao Z, Xue Y. Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China. *Frontiers in Public Health*. 2023 May 9;11:1117101. doi: 10.3389/fpubh.2023.1117101
38. Kostyukova I, Pasechnik O, Mokrousov I. Epidemiology and drug resistance patterns of *Mycobacterium tuberculosis* in High-Burden Area in Western Siberia, Russia. *Microorganisms*. 2023 Feb 8;11(2):425. doi: 10.3390/microorganisms11020425
39. CDC, Drug-Resistant tuberculosis disease [Internet]. Reported Tuberculosis in the United States, 2023. 2024. Available from: <https://www.cdc.gov/tb-surveillance-report-2023/summary/drug-resistant>.
40. Bhattacharyya K, Jha RP, Dhamnetiya D, Patel P, Shri N, Singh M. Exploring secular trends and types of tuberculosis burden in India over past three decades through insights from the Global Burden of Disease Study 2019. *Discover Public Health*. 2025 Jul 28;22(1):439. DOI: 10.1186/s12982-025-00772-7
41. Madaki S, Mohammed Y, Rogo LD, Yusuf M, Bala YG. Age and gender in drug resistance tuberculosis: A cross-sectional case study at a national tuberculosis reference hospital in Nigeria. *Journal of Global Antimicrobial Resistance*. 2024 Dec 1;39:175-83. doi: 10.1016/j.jgar.2024.09.002
42. Salari N, Kanjoori AH, Hosseinian-Far A, Hasheminezhad R, Mansouri K, Mohammadi M. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. *Infectious diseases of poverty*. 2023 May 25;12(1):57. DOI: 10.1186/s40249-023-01107-x
43. World Health Organization. 1.3 Drug-resistant TB [Internet]. *Who.int*. 2022. Available from: <https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024/tb-disease-burden/1-3-drug-resistant-tb>

44. Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, Armitige L. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. *Emerging infectious diseases*. 2014 May;20(5):812. doi: 10.3201/eid2005.131037
45. Husain AA, Kupz A, Kashyap RS. Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications. *Epidemiology and Health*. 2021 Apr 7;43:e2021022. doi: 10.4178/epih.e2021022
46. Matteelli A, Lovatti S, Rossi B, Rossi L. Update on multidrug-resistant tuberculosis preventive therapy toward the global tuberculosis elimination. *International Journal of Infectious Diseases*. 2025 Jun 1;155:doi: 10.1016/j.ijid.2025.107849
47. Zhai PY, Chen ZX, Jiang T, Feng J, Zhang B, Zang X, Zhao YL, Qin G. Modeling the epidemiologic impact of age-targeted vaccination for drug-resistant tuberculosis. *Drug Resistance Updates*. 2025 Jan 1;78:101172. doi: 10.1016/j.drug.2024.101172.
48. Masita M, Hairi FM, Bachtiar A, Mulyana N, Andriani H. Community-driven strategies and policies for drug-resistant tuberculosis control in Banyumas Regency, Indonesia: A comprehensive 2023 analysis. *Journal of Public Health Research*. 2025 Sep;14(3):22799036251376872. doi: 10.1177/22799036251376872
49. Mughal MA, Imran A, Khan HU, Farooq M, Ikram A, Arshad F, Ashraf R, Khatoon F. Prevalence of Multidrug-Resistant Tuberculosis and Its Association With Previous Treatment History in Adults. *Cureus*. 2025 Jul 17;17(7). doi: 10.7759/cureus.88204
50. Sougakoff W. Molecular epidemiology of multidrug-resistant strains of *Mycobacterium tuberculosis*. *Clinical Microbiology and Infection*. 2011 Jun 1;17(6):800-5. doi: 10.1111/j.1469-0691.2011.03577.x.
51. Müller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant *Mycobacterium tuberculosis*. *Trends in Genetics*. 2013 Mar 1;29(3):160-9. doi: 10.1016/j.tig.2012.11.005.
52. Erie H, Kaboosi H, Javid N, Shirzad-Aski H, Taziki M, Kuchaksaraee MB, Ghaemi EA. The high prevalence of *Mycobacterium tuberculosis* Beijing strain at an early age and extra-pulmonary tuberculosis cases. *Iranian journal of microbiology*. 2017 Dec;9(6):312. PMID: 29487728, PMCID: PMC5825930
53. Gupta A, Sinha P, Nema V, Gupta PK, Chakraborty P, Kulkarni S, Rastogi N, Anupurba S. Detection of Beijing strains of MDR *M. tuberculosis* and their association with drug resistance mutations in *katG*, *rpoB*, and *embB* genes. *BMC infectious diseases*. 2020 Oct 14;20(1):752. doi: 10.1186/s12879-020-05479-5.
54. Nikolayevskyy VV, Brown TJ, Bazhora YI, Asmolov AA, Balabanova YM, Drobniowski FA. Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in *Mycobacterium tuberculosis* strains from the southern Ukraine. *Clinical microbiology and infection*. 2007 Feb 1;13(2):129-38. doi: 10.1111/j.1469-0691.2006.01583.x.
55. Zhang Z, Zhang Q, Wang T, Xu N, Lu T, Hong W, Penuelas J, Gillings M, Wang M, Gao W, Qian H. Assessment of global health risk of antibiotic resistance genes. *Nature communications*. 2022 Mar 23;13(1):1553. <https://doi.org/10.1038/s41467-022-29283-8>
56. Nimmo C, Millard J, Faulkner V, Monteserin J, Pugh H, Johnson EO. Evolution of *Mycobacterium tuberculosis* drug resistance in the genomic era. *Frontiers in Cellular and Infection Microbiology*. 2022 Oct 7;12:954074. doi: 10.3389/fcimb.2022.954074.
57. Shrivasa A, Singh S. Tuberculosis diagnosis and management: recent advances. *Journal of Global Infectious Diseases*. 2025 Jan 1;17(1):3-9. doi: 10.4103/jgid.jgid_112_24.
58. Gupta A, Kulkarni S, Rastogi N, Anupurba S. A study of *Mycobacterium tuberculosis* genotypic diversity & drug resistance mutations in Varanasi, north India. *Indian Journal of Medical Research*. 2014 Jun 1;139(6):892-902. PMCID: PMC4165002 PMID: 25109724
59. Devi KR, Pradhan J, Bhutia R, Dadul P, Sarkar A, Gohain N, Narain K. Molecular diversity of *Mycobacterium tuberculosis* complex in Sikkim, India and prediction of dominant spoligotypes using artificial intelligence. *Scientific Reports*. 2021 Apr 1;11(1):7365. <https://doi.org/10.1038/s41598-021-86626-z>
60. Unissa AN, Selvakumar N, Narayanan S, Suganthi C, Hanna LE. Investigation of Ser315 Substitutions within *katG* Gene in Isoniazid-Resistant Clinical Isolates of *Mycobacterium tuberculosis* from South India. *BioMed Research International*. 2015;2015(1):257983. doi: 10.1155/2015/257983
61. Unissa AN, Kumar T, Sukumar S, Lakshmi AR, Hanna LE. Significance of catalase-peroxidase (*KatG*) mutations in mediating isoniazid resistance in clinical strains of *Mycobacterium tuberculosis*. *Journal of global antimicrobial resistance*. 2018 Dec 1;15:111-20. doi: 10.1016/j.jgar.2018.07.001.
62. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A. Characterization of *rpoB* mutations in rifampin-resistant clinical isolates of *Mycobacterium tuberculosis* from Turkey by DNA sequencing and line probe assay. *Journal of clinical microbiology*. 2002 Dec;40(12):4435-8. doi: 10.1128/JCM.40.12.4435-4438.2002.

63. Komakech K, Nakiyingi L, Fred A, Achan B, Joloba M, Kirenga BJ, Ssengooba W. Effect of mixed *Mycobacterium tuberculosis* infection on rapid molecular diagnostics among patients starting MDR-TB treatment in Uganda. BMC Infectious Diseases. 2024 Jan 10;24(1):70.doi: 10.1186/s12879-023-08968-5.
64. Mujuni D, Kasemire DL, Ibanda I, Kabugo J, Nsawotebba A, Phelan JE, Majwala RK, Tugumisirize D, Nyombi A, Orena B, Turyahabwe I. Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year's review. BMC Infectious Diseases. 2022 Apr 11;22(1):363.doi: 10.1186/s12879-022-07339-w.
65. Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L, Carter EJ, Rockwood N. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. The Lancet Infectious diseases. 2019 Mar 1;19(3):298-307.DOI: 10.1016/S1473-3099(18)30673-X External Link
66. Li S, Liu B, Peng M, Chen M, Yin W, Tang H, Luo Y, Hu P, Ren H. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis. PloS one. 2017 Jul 14;12(7):e0180725.doi.org/10.1371/journal.pone.0180725
67. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablshvili N. Xpert MTB/RIF Ultra for detection of *Mycobacterium tuberculosis* and rifampicin resistance: a prospective multicentre diagnostic accuracy study. The Lancet infectious diseases. 2018 Jan 1;18(1):76-84. Doi: 10.1016/S1473-3099(17)30691-6.
68. Kipiani, M., Graciaa, D.S., Buziashvili, M., Darchia, L., Avaliani, Z., Tabagari, N., Mirtskhulava, V. and Kempker, R.R., 2021, December. Xpert MTB/RIF use is associated with earlier treatment initiation and culture conversion among patients with sputum smear-negative multidrug-resistant tuberculosis. In Open Forum Infectious Diseases (Vol. 8, No. 12, p. ofab551). US: Oxford University Press. Doi: 10.1093/ofid/ofab551.
69. Kanade S, Mohammed Z, Kulkarni A, Nataraj G. Comparison of Xpert MTB/RIF assay, line probe assay, and culture in diagnosis of pulmonary tuberculosis on bronchoscopic specimen. The International Journal of Mycobacteriology. 2023 Apr 1;12(2):151-6.doi: 10.4103/ijmy.ijmy_86_23
70. Naidoo K, Perumal R, Ngema SL, Shunmugam L, Somboro AM. Rapid diagnosis of drug-resistant tuberculosis—opportunities and challenges. Pathogens. 2023 Dec 27;13(1):27.doi: 10.3390/pathogens13010027.
71. Tawfick MM, Badawy MS, Taleb MH, Menofy NG. Tuberculosis Diagnosis and Detection of Drug Resistance: A Comprehensive Updated Review. Journal of Pure & Applied Microbiology. 2023 Dec 1;17(4).https://doi.org/10.22207/JPAM.17.4.56
72. Mousavi-Sagharchi SM, Afrazeh E, Seyyedean-Nikjeh SF, Meskini M, Doroud D, Siadat SD. New insight in molecular detection of *Mycobacterium tuberculosis*. Amb Express. 2024 Jun 21;14(1):74.https://doi.org/10.1186/s13568-024-01730-3
73. Pai M, Dewan PK, Swaminathan S. Transforming tuberculosis diagnosis. Nature Microbiology. 2023 May;8(5):756-9.doi: 10.1038/s41564-023-01365-3.
74. Hoel IM, Syre H, Skarstein I, Mustafa T. Xpert MTB/RIF ultra for rapid diagnosis of extrapulmonary tuberculosis in a high-income low-tuberculosis prevalence setting. Scientific Reports. 2020 Aug 18;10(1):13959.doi: 10.1038/s41598-020-70613-x.
75. Schwab TC, Perrig L, Göller PC, De la Hoz FF, Lahousse AP, Minder B, Günther G, Efthimiou O, Omar SV, Egger M, Fenner L. Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2024 Oct 1;24(10):1162-76. Doi: 10.1016/S1473-3099(24)00263-9
76. Kumawat B, Puri MM, Bhalla M, Prabhu A, Sharma N, Singh P, Kumar R. TB LAMP-a potential way forward to diagnose Smear Negative Suspected TB Cases. Indian Journal of Tuberculosis. 2025 Jul 1. Doi: 10.1016/j.ijtb.2025.06.018
77. Flores LL, Steingart KR, Dendukuri N, Schiller I, Minion J, Pai M, Ramsay A, Henry M, Laal S. Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis. Clinical and Vaccine Immunology. 2011 Oct;18(10):1616-27. Doi: 10.1128/CVI.05205-11.
78. Schiff HF, Walker NF, Ugarte-Gil C, Tebruegge M, Manousopoulou A, Garbis SD, Mansour S, Wong PH, Rockett G, Piazza P, Niranjana M. Integrated plasma proteomics identifies tuberculosis-specific diagnostic biomarkers. JCI insight. 2024 Mar 21;9(8):e173273.doi: 10.1172/jci.insight.173273
79. Comella-del-Barrio P, Abellana R, Villar-Hernández R, Jean Coute MD, SallésMingels B, Canales Aliaga L, Narcisse M, Gautier J, Ascaso C, Latorre I, Dominguez J. A model based on the combination of IFN- γ , IP-10, ferritin and 25-hydroxyvitamin D for discriminating latent from active tuberculosis in children. Frontiers in microbiology. 2019 Aug 14;10:1855.doi:10.3389/fmicb.2019.01855

80. Druszczynska M, Seweryn M, Wawrocki S, Pankowska A, Kulbachko A, Jurczak M, Kowalewska-Pietrzak M. Interferon (IFN)-gamma (γ) inducible protein 10 (IP-10) in the diagnosis of latent and active tuberculosis in Bacille Calmette Guerin (BCG)-vaccinated pediatric population. *Plos one*. 2025 Jan 21;20(1):e0314400.doi:10.1371/journal.pone.0314400
81. Qian Z, Liu H, Li M, Shi J, Li N, Zhang Y, Zhang X, Lv J, Xie X, Bai Y, Ge Q. Potential diagnostic power of blood circular RNA expression in active pulmonary tuberculosis. *EBioMedicine*. 2018 Jan 1;27:18-26. Doi: 10.1016/j.ebiom.2017.12.007
82. Jaya T, Bijay P, Divyanjali R, Naveen B, Adwika PP, Sunil B, Yadav S, Kumari S, Verma U, Yadav G, Dhaliwal RS. MicroRNAs in exhaled breath Condensate: Novel non-invasive biomarkers for tuberculosis diagnosis. *Tuberculosis*. 2025 Sep 1;154:102670.<https://doi.org/10.1016/j.tube.2025.102670>
83. Cao XF, Li Y, Xin HN, Zhang HR, Pai M, Gao L. Application of artificial intelligence in digital chest radiography reading for pulmonary tuberculosis screening. *Chronic Diseases and Translational Medicine*. 2021 Mar 1;7(01):35-40.doi: 10.1016/j.cdtm.2021.02.001
84. Devasia J, Goswami H, Lakshminarayanan S, Rajaram M, Adithan S. Deep learning classification of active tuberculosis lung zones wise manifestations using chest X-rays: a multi label approach. *Scientific Reports*. 2023 Jan 17;13(1):887.doi:10.1038/s41598-023-28079-0
85. de Camargo TF, Ribeiro GA, da Silva MC, da Silva LO, Torres PP, Rodrigues DD, de Santos MO, Filho WS, Rosa ME, Novaes MD, Massarutto TA. Clinical validation of an artificial intelligence algorithm for classifying tuberculosis and pulmonary findings in chest radiographs. *Frontiers in Artificial Intelligence*. 2025 Feb 6;8:1512910.doi:10.3389/frai.2025.1512910.
86. Sharma A, Machado E, Lima KV, Suffys PN, Conceição EC. Tuberculosis drug resistance profiling based on machine learning: A literature review. *The Brazilian Journal of Infectious Diseases*. 2022 Jan 1;26(1):102332. Doi: 10.1016/j.bjid.2022.102332.
87. Hosu MC, Faye LM, Apalata T. Predicting treatment outcomes in patients with drug-resistant tuberculosis and human immunodeficiency virus coinfection, using supervised machine learning algorithm. *Pathogens*. 2024 Oct 24;13(11):923.doi:10.3390/pathogens13110923
88. Zhang F, Yang Z, Geng X, Dong Y, Li S, Yao C, Shang Y, Ren W, Liu R, Kuang H, Li L. Using Machine Learning Methods to Predict Early Treatment Outcomes for Multidrug-Resistant or Rifampicin-Resistant Tuberculosis to Enhance Patient Cure Rates: Development and Validation of Multiple Models. *Journal of Medical Internet Research*. 2025 Sep 22;27:e69998.doi: 10.2196/69998.
89. Thoma Y, Cathignol AE, Pétermann YJ, Sariko ML, Said B, Csajka C, Guidi M, Mpagama SG. Toward a clinical decision support system for monitoring therapeutic antituberculosis medical drugs in Tanzania (project TuberXpert): protocol for an algorithm development and implementation. *JMIR research protocols*. 2024 Oct 21;13(1):e58720.doi:10.2196/58720.
90. Olawade DB, Eberhardt J, David-Olawade AC, Balogun MA, Bolarinwa OA, Esan DT. Transforming multidrug-resistant tuberculosis care: The potentials of telemedicine in resource-limited settings. *Health Sciences Review*. 2024 Sep 1;12:100185. Doi: 10.1016/j.hsr.2024.100185
91. Ghosh P, Anwar S, Siegel M, Okuni JB, Weidmann M, Mithila NT, Cassar K, Müller SE, Luba FR, Kobialka RM, Dey BP. Assessing the performance of a point-of-need diagnostic algorithm in rapid detection of peripheral lymph node tuberculosis (Mobile-TB-Lab): a diagnostic evaluation study protocol. *BMJ open*. 2025 May 1;15(5):e097001. Doi: 10.1136/bmjopen-2024-097001.
92. Swinkels HM, Jilani TN, Tobin EH. Tuberculosis Prevention, Control, and Elimination. [Updated 2025 Jul 6]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513246/>
93. Kant S, Tyagi R. The impact of COVID-19 on tuberculosis: challenges and opportunities. *Therapeutic advances in infectious disease*. 2021 Jun;8:20499361211016973.doi: 10.1177/20499361211016973
94. Jindani A, Hatherill M, Smith R, et al. Efficacy and Safety of 4-Month Rifapentine-Based Regimen for Drug-Sensitive Tuberculosis: A Randomized Clinical Trial. *Emerg Infect Dis*. 2025 Mar 2;31(3):xxx-xxx. Available from: https://wwwnc.cdc.gov/eid/article/31/3/24-1634_article [accessed 2025 Oct 13].
95. Nahid P, Guta A, Barker RD, et al. Treatment of Drug-Resistant and Drug-Susceptible Tuberculosis: 2025 Update. *Clin Infect Dis*. 2024 Dec 29. Available from: <https://www.idsociety.org/practice-guideline/treatment-of-drug-susceptible-tb/treatment-of-drug-resistant-and-drug-susceptible-tb-2025-update/> [accessed 2025 Oct 13].
96. World Health Organization. Launch of TB-Free Central Asia Initiative, Astana, Kazakhstan, 7 April 2025. WHO Regional Office for Europe; 2025 Apr 7 [cited 2025 Oct 15]. Available from:

- <https://www.who.int/europe/news-room/events/item/2025/04/07/default-calendar/launch-of-tb-free-central-asia-initiative>
97. Ministry of Health and Family Welfare, Government of India. National Guidelines for Management of Drug Resistant Tuberculosis, 2025. New Delhi: Central TB Division; 2025. Available from: https://tbcindia.mohfw.gov.in/wp-content/uploads/2025/01/National-Guidelines-for-Management-of-DR-TB_Final.pdf [accessed 2025 Oct 13].
 98. Guglielmetti, L., Khan, U., Velásquez, G.E., Gouillou, M., Ali, M.H., Amjad, S., Kamal, F., Abubakirov, A., Ardizzoni, E., Baudin, E. and Bektassov, S., 2025. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. *The Lancet Respiratory Medicine*, 13(9), pp.809-820. Doi: 10.1016/S2213-2600(25)00194-8
 99. Fekadu G, Tolossa T, Bekele F, Chen X, He Y, Yu J, Yi X, Liu M, Fetensa G, Dugassa D, Turi E. Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. *BMJ Global Health*. 2025 Apr 7;10(4). Doi: 10.1136/bmjgh-2024-018220.
 100. Lan SH, Lin WT, Chang SP, Lu LC, Chao CM, Lai CC, Wang JH. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis. *Antibiotics*. 2019 Sep 4;8(3):137. doi: 10.3390/antibiotics8030137.
 101. Chen RH, Burke A, Cho JG, Alffenaar JW, Davies Forsman L. New oxazolidinones for tuberculosis: are novel treatments on the horizon?. *Pharmaceutics*. 2024 Jun 17;16(6):818. Doi: 10.3390/pharmaceutics16060818.
 102. Payen MC, Muylle I, Vandenberg O, Mathys V, Delforge M, Van den Wijngaert S, Clumeck N, De Wit S. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases. *The International Journal of Tuberculosis and Lung Disease*. 2018 Jan 1;22(1):34-9. Doi: 10.5588/ijtld.17.0352.
 103. van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. Evaluation of carbapenems for treatment of multi-and extensively drug-resistant *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy*. 2019 Feb;63(2):10-128. Doi: 10.1128/AAC.01489-18
 104. Jing W, Wang Q, Wang J, Ma L, Huang M, Wang J, Du Y, Cai B, Shi W, Li Q, Li X. New all-oral short-term regimen for multidrug-resistant tuberculosis: A semi-randomized controlled trial conducted in China. In *Open Forum Infectious Diseases* 2025 Feb (Vol. 12, No. 2, p. ofaf020). US: Oxford University Press.
 105. Permatasari A, Agustiyanto C, Rampengan VR. Limited Success and High Attrition in the 9-Month All-Oral Regimen for MDR-TB: Evidence from a Tertiary Care Setting in Indonesia. *Indian Journal of Tuberculosis*. 2025 Aug 5. Doi: 10.1016/j.ijtb.2025.08.001
 106. Metarfi Y, Chellal W, Ben Khadda Z, Hoummani H, Amara B, Achour S. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review. *J Antimicrob Chemother*. 2025 Jun 3;80(6):1508-1518. doi: 10.1093/jac/dkaf126.
 107. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. *Cochrane Database of Systematic Reviews*. 2010 Jan 19;(1):CD000171. doi:10.1002/14651858.CD000171.pub3.
 108. Al Maani A, Petersen E, Memish ZA. The critical role of new tuberculosis vaccines in achieving the WHO 2035 End TB target. *IJID regions*. 2025 Mar 1;14:100595. doi.org/10.1016/j.ijregi.2025.100595
 109. Vilaplana C, Gil O, Cáceres N, Pinto S, Díaz J, Cardona PJ. Prophylactic effect of a therapeutic vaccine against TB based on fragments of *Mycobacterium tuberculosis*. *PloS one*. 2011 May 24;6(5):e20404. Doi: org/10.1371/journal.pone.0020404
 110. Ministry of Health and Family Welfare, Government of India. National Tuberculosis Elimination Programme (NTEP). New Delhi: MoHFW; 2022. Available from: <https://dghs.mohfw.gov.in/national-tuberculosis-elimination-programme.php> [accessed October 2025]
 111. Hayibor KM, Mensah GI, Kenu E, Awalime D, Anaman J, Asante-Poku A, Ivanova O, Bakuli A, Rachow A, Hanson-Nortey NN. Scaling up tuberculosis case finding via private providers in Ghana: an impact evaluation using interrupted time series. *Frontiers in Public Health*. 2025 Aug 26;13:1598269. Doi: org/10.3389/fpubh.2025.1598269
 112. Kia P, Ruman U, Pratiwi AR, Hussein MZ. Innovative therapeutic approaches based on nanotechnology for the treatment and management of tuberculosis. *International journal of nanomedicine*. 2023 Dec 31:1159-91. doi: 10.2147/IJN.S364634.
 113. Olowoyo KS, Esan DT, Adeyanju BT, Olawade DB, Oyinloye BE, Olowoyo P. Telemedicine as a tool to prevent multi-drug resistant tuberculosis in poor resource settings: Lessons from Nigeria. *Journal of Clinical*

- Tuberculosis and Other Mycobacterial Diseases. 2024 May 1;35:100423. Doi: org/10.1016/j.jctube.2024.100423
114. Yang F, Labani-Motlagh A, Bohorquez JA, Moreira JD, Ansari D, Patel S, Spagnolo F, Florence J, Vankayalapati A, Sakai T, Sato O. Bacteriophage therapy for the treatment of *Mycobacterium tuberculosis* infections in humanized mice. *Communications Biology*. 2024 Mar 9;7(1):294. Doi: 10.1038/s42003-024-06006-x.
115. Miladi QN, Pahlia T, Pramukti I. Effectiveness of Digital Health Interventions to Enhance Continuity of Care in Patients with Pulmonary Tuberculosis: A Systematic Review of Randomized Controlled Trials. *Patient preference and adherence*. 2025 Dec 31:1807-23. Doi: org/10.2147/PPA.S533210
116. Tian N, Chu H, Li Q, Sun H, Zhang J, Chu N, Sun Z. Host-directed therapy for tuberculosis. *European Journal of Medical Research*. 2025 Apr 11;30(1):267. <https://doi.org/10.1186/s40001-025-02443-4>
117. Strong EJ, Lee S. Targeting autophagy as a strategy for developing new vaccines and host-directed therapeutics against mycobacteria. *Frontiers in microbiology*. 2021 Jan 14;11:614313. <https://doi.org/10.3389/fmicb.2020.614313>
118. Dekkers BG, Kerstjens HA, Breisnes HW, Leeming DJ, Anthony RM, Frijlink HW, van der Werf TS, Kosterink JG, Alffenaar JW, Akkerman OW. Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial. *The Journal of Infectious Diseases*. 2025 May 15;231(5):e891-900. doi: 10.1093/infdis/jiaf069.
119. Kumar M, Virmani T, Kumar G, Deshmukh R, Sharma A, Duarte S, Brandão P, Fonte P. Nanocarriers in tuberculosis treatment: challenges and delivery strategies. *Pharmaceuticals*. 2023 Sep 26;16(10):1360. Doi: doi.org/10.3390/ph16101360
120. Zhuo Y, Zhao YG, Zhang Y. Enhancing drug solubility, bioavailability, and targeted therapeutic applications through magnetic nanoparticles. *Molecules*. 2024 Oct 13;29(20):4854. doi: 10.3390/molecules29204854
121. Olowoyo KS, Esan DT, Olowoyo P, Oyinloye BE, Fawole IO, Aderibigbe S, Adigun MO, Olawade DB, Esan TO, Adeyanju BT. Treatment adherence and outcomes in patients with Tuberculosis treated with Telemedicine: A scoping review. *Tropical Medicine and Infectious Disease*. 2025 Mar 17;10(3):78. Doi: 10.3390/tropicalmed10030078
122. Iribarren S, Aguilar Vidrio OA, Roberti J, Goodwin K, Chirico C, Telles H, Lutz B, Bornengo F, Rubinstein F. User-Centered Refinement of a Digital Tool for Tuberculosis Treatment Support: Iterative Mixed Methods Study. *Journal of Medical Internet Research*. 2025 Jul 30;27:e76742. Doi: 10.2196/76742.
123. Bhargava K, Nath G, Bhargava A, Aseri GK, Jain N. Phage therapeutics: from promises to practices and prospectives. *Applied Microbiology and Biotechnology*. 2021 Dec;105(24):9047-67. Doi: 10.1007/s00253-021-11695-z
124. Olawade DB, Fapohunda O, Egbon E, Ebiesuwa OA, Usman SO, Faronbi AO, Fidelis SC. Phage therapy: A targeted approach to overcoming antibiotic resistance. *Microbial Pathogenesis*. 2024 Dec 1;197:107088. Doi: 10.1016/j.micpath.2024.107088
125. Azimi T, Mosadegh M, Nasiri MJ, Sabour S, Karimaei S, Nasser A. Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review. *Infection and Drug Resistance*. 2019 Sep 17:2943-59. Doi: 10.0.2147/IDR.S218638
126. Borysowski J, Weber-Dąbrowska B, Górski A. Bacteriophage endolysins as a novel class of antibacterial agents. *Experimental biology and medicine*. 2006 Apr;231(4):366-77. Doi: 10.1177/153537020623100402
127. Hermoso JA, García JL, García P. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. *Current opinion in microbiology*. 2007 Oct 1;10(5):461-72. Doi: 10.1016/j.mib.2007.08.002
128. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant *Staphylococcus aureus*. *Antimicrobial agents and chemotherapy*. 2010 Apr;54(4):1603-12. Doi: 10.1128/AAC.01625-09
129. Gil F, Grzegorzewicz AE, Catalao MJ, Vital J, McNeil MR, Pimentel M. Mycobacteriophage Ms6 LysB specifically targets the outer membrane of *Mycobacterium smegmatis*. *Microbiology*. 2010 May;156(5):1497-504. Doi: org/10.1099/mic.0.032821-0
130. Li Q, Zhou M, Fan X, Yan J, Li W, Xie J. Mycobacteriophage SWU1 gp39 can potentiate multiple antibiotics against *Mycobacterium* via altering the cell wall permeability. *Scientific reports*. 2016 Jun 28;6(1):28701. Doi: org/10.1038/srep28701
131. Du Plessis J, Cloete R, Burchell L, Sarkar P, Warren RM, Christoffels A, Wigneshweraraj S, Sampson SL. Exploring the potential of T7 bacteriophage protein Gp2 as a novel inhibitor of mycobacterial RNA polymerase. *Tuberculosis*. 2017 Sep 1;106:82-90. Doi: 10.1016/j.tube.2017.07.004

132. Ghosh G, Reddy J, Sambhare S, Sen R. A bacteriophage capsid protein is an inhibitor of a conserved transcription terminator of various bacterial pathogens. *Journal of Bacteriology*. 2018 Jan 1;200(1):10-128. Doi: 10.1128/JB.00380-17
133. Jeyasankar S, Kalapala YC, Sharma PR, Agarwal R. Antibacterial efficacy of mycobacteriophages against virulent *Mycobacterium tuberculosis*. *BMC microbiology*. 2024 Sep 4;24(1):320. Doi: org/10.1186/s12866-024-03474-3
134. Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, Whitney Brown A, Cohen KA, Davidson RM, van Duin D, Gainey A. Phage therapy of *Mycobacterium* infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. *Clinical infectious diseases*. 2023 Jan 1;76(1):103-12. Doi: 10.1093/cid/ciac453.
135. Loganathan A, Bozdogan B, Manohar P, Nachimuthu R. Phage-antibiotic combinations in various treatment modalities to manage MRSA infections. *Frontiers in pharmacology*. 2024 Apr 9;15:1356179. Doi: 10.3389/fphar.2024.1356179
136. Stop TB Partnership. The Global Plan to End TB 2023–2030. Geneva: Stop TB Partnership; 2022. Available from: <https://www.stoptb.org/what-we-do/advocate-endtb/global-plan-end-tb/global-plan-end-tb-2023-2030> [accessed October 2025]
137. Al Awaidy S, Khamis F, Al Mujeini S, Al Salman J, Al-Tawfiq JA. Ending Tuberculosis in GCC countries: A overview of the WHO End TB Strategy 2025 Milestones. *IJID Regions*. 2025 Jun 6:100681. Doi: 10.1016/j.ijregi.2025.100681
138. Akalu TY, Clements AC, Wolde HF, Alene KA. Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis. *Scientific Reports*. 2023 Dec 15;13(1):22361. <https://doi.org/10.1038/s41598-023-47094-9>
139. Gilmour B, Alene KA. Ending tuberculosis: Challenges and opportunities. *Frontiers in Tuberculosis*. 2024 Dec 24;2:1487518. Doi: org/10.3389/ftubr.2024.1487518
140. Iradukunda A, Getnet F, Odjidja EN. Tuberculosis mortality and drug resistance among patients under TB treatment before and during COVID-19 in Burundi: a case–control study. *BMC Infectious Diseases*. 2025 May 17;25(1):716. Doi: 10.1186/s12879-025-11093-0